Skip Navigation
 
 
 
 xxx
 
 
 
 
 
 
 
 
 
Print This Page
Share this page: More
 

Richard E. Chaisson, M.D

Richard E. Chaisson, M.D.
Director of the Johns Hopkins Center for Tuberculosis Research

 Email Dr. Chaisson

Richard E. Chaisson, M.D., is Professor of Medicine, Epidemiology and International Health at the Johns Hopkins University in Baltimore.  He received his BS and MD degrees from the University of Massachusetts, and was an intern, resident and fellow at the University of California, San Francisco, where he was also Assistant Professor of Medicine.  From 1988-1998 he was director of the Johns Hopkins AIDS Service, and he co-founded the Johns Hopkins HIV Clinic cohort, an observational study that has been the source of more than 130 scientific publications on the outcomes of HIV disease and its treatment. 

Dr. Chaisson is currently Director of the Johns Hopkins Center for Tuberculosis Research, a multidisciplinary center with more than $60 million in grants for the study of TB from bench to bedside. Dr. Chaisson's research interests focus on tuberculosis and HIV infection, including global epidemiology, clinical trials, diagnostics and public health interventions.  He is currently principal investigator of 11 research grants, and is director of the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), an international research consortium funded by the Bill and Melinda Gates Foundation to assess the impact of novel strategies for controlling HIV-related TB.  He has published over 300 scientific papers and book chapters.

Click to read a profile of Dr. Chaisson that appeared in the January, 2005, issue of Nature Medicine.

Publications

To read some of these publications online, click here. Please note that to read the full text of some of these articles requires that you have an online subscription to the journal.

Peer-Reviewed Articles

1.    Ribeiro, S., K. Dooley, J. Hackman, C. Loredo, A. Efron, R. E. Chaisson, M. B. Conde, N. Boechat, and S. E. Dorman. 2009. T-SPOT.TB responses during treatment of pulmonary tuberculosis. BMC Infect Dis 9:23.
2.    Nachega, J. B., M. Hislop, H. Nguyen, D. W. Dowdy, R. E. Chaisson, L. Regensberg, M. Cotton, and G. Maartens. 2009. Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern Africa. J Acquir Immune Defic Syndr.
3.    Deluca, A., R. E. Chaisson, and N. A. Martinson. 2009. Intensified case finding for tuberculosis in prevention of mother-to-child transmission programs: a simple and potentially vital addition for maternal and child health. J Acquir Immune Defic Syndr 50:196-9.
4.    Conde, M. B., A. Efron, C. Loredo, G. R. De Souza, N. P. Graca, M. C. Cezar, M. Ram, M. A. Chaudhary, W. R. Bishai, A. L. Kritski, and R. E. Chaisson. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomized, controlled phase II trial. Lancet 373:1183-9.
5.    Chaisson, R. E., and M. Harrington. 2009. How research can help control tuberculosis. Int J Tuberc Lung Dis 13:558-68.
6.    Cailleaux-Cezar, M., A. M. D. de, G. M. Xavier, C. L. de Salles, F. C. de Mello, A. Ruffino-Netto, J. E. Golub, A. Efron, R. E. Chaisson, and M. B. Conde. 2009. Tuberculosis incidence among contacts of active pulmonary tuberculosis. Int J Tuberc Lung Dis 13:190-5.
7.    Aguiar, F., M. A. Vieira, A. Staviack, C. Buarque, A. Marsico, L. Fonseca, R. Chaisson, A. Kristski, G. Werneck, and F. Mello. 2009. Prevalence of anti-tuberculosis drug resistance in an HIV/AIDS reference hospital in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 13:54-61.
8.    Saraceni, V., B. S. King, S. C. Cavalcante, J. E. Golub, L. M. Lauria, L. H. Moulton, R. E. Chaisson, and B. Durovni. 2008. Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 12:769-72.
9.    Pope, D. S., A. N. Deluca, P. Kali, H. Hausler, C. Sheard, E. Hoosain, M. A. Chaudhary, D. D. Celentano, and R. E. Chaisson. 2008. A cluster-randomized trial of provider-initiated (opt-out) HIV counseling and testing of tuberculosis patients in South Africa. J Acquir Immune Defic Syndr 48:190-5.
10.    Pacheco, A. G., V. Saraceni, S. H. Tuboi, L. H. Moulton, R. E. Chaisson, S. C. Cavalcante, B. Durovni, J. C. Faulhaber, J. E. Golub, B. King, M. Schechter, and L. H. Harrison. 2008. Validation of a hierarchical deterministic record-linkage algorithm using data from 2 different cohorts of human immunodeficiency virus-infected persons and mortality databases in Brazil. Am J Epidemiol 168:1326-32.
11.    Pacheco, A. G., B. Durovni, S. C. Cavalcante, L. M. Lauria, R. D. Moore, L. H. Moulton, R. E. Chaisson, and J. E. Golub. 2008. AIDS-related tuberculosis in Rio de Janeiro, Brazil. PLoS ONE 3:e3132.
12.    Nachega, J. B., M. Hislop, D. W. Dowdy, J. E. Gallant, R. E. Chaisson, L. Regensberg, and G. Maartens. 2008. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. Aids 22:2117-25.
13.    Hoffmann, C. J., S. Charalambous, D. J. Martin, C. Innes, G. J. Churchyard, R. E. Chaisson, A. D. Grant, K. L. Fielding, and C. L. Thio. 2008. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 47:1479-85.
14.    Golub, J. E., B. Durovni, B. S. King, S. C. Cavalacante, A. G. Pacheco, L. H. Moulton, R. D. Moore, R. E. Chaisson, and V. Saraceni. 2008. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. Aids 22:2527-33.
15.    Golub, J. E., J. Astemborski, M. Ahmed, W. Cronin, S. H. Mehta, G. D. Kirk, D. Vlahov, and R. E. Chaisson. 2008. Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users. J Acquir Immune Defic Syndr 49:532-7.
16.    Dowdy, D. W., M. C. Lourenco, S. C. Cavalcante, V. Saraceni, B. King, J. E. Golub, D. Bishai, B. Durovni, R. E. Chaisson, and S. E. Dorman. 2008. Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS ONE 3:e4057.
17.    Dowdy, D. W., R. E. Chaisson, G. Maartens, E. L. Corbett, and S. E. Dorman. 2008. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A 105:11293-8.
18.    Dooley, K., C. Flexner, J. Hackman, C. A. Peloquin, E. Nuermberger, R. E. Chaisson, and S. E. Dorman. 2008. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 52:4037-42.
19.    Charalambous, S., A. D. Grant, V. Moloi, R. Warren, J. H. Day, P. van Helden, R. J. Hayes, K. L. Fielding, K. M. De Cock, R. E. Chaisson, and G. J. Churchyard. 2008. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis 12:942-8.
20.    Chaisson, R. E., and N. A. Martinson. 2008. Tuberculosis in Africa--combating an HIV-driven crisis. N Engl J Med 358:1089-92.
21.    Wilson, D., J. Nachega, C. Morroni, R. Chaisson, and G. Maartens. 2006. Diagnosing smear-negative tuberculosis using case definitions and treatment response in HIV-infected adults. Int J Tuberc Lung Dis 10:31-8.
22.    Sterling, T. R., Z. Zhao, A. Khan, R. E. Chaisson, N. Schluger, B. Mangura, M. Weiner, and A. Vernon. 2006. Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis 10:542-9.
23.    Soares, E. C., A. G. Pacheco, F. C. Mello, B. Durovni, R. E. Chaisson, and S. C. Cavalcante. 2006. Improvements in treatment success rates with directly observed therapy in Rio de Janeiro City. Int J Tuberc Lung Dis 10:690-5.
24.    Schechter, M., R. Zajdenverg, G. Falco, G. L. Barnes, J. C. Faulhaber, J. S. Coberly, R. D. Moore, and R. E. Chaisson. 2006. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 173:922-6.
25.    Mello, F. C., L. G. Bastos, S. L. Soares, V. M. Rezende, M. B. Conde, R. E. Chaisson, A. L. Kritski, A. Ruffino-Netto, and G. L. Werneck. 2006. Predicting smear negative pulmonary tuberculosis with classification trees and logistic regression: a cross-sectional study. BMC Public Health 6:43.
26.    Golub, J. E., S. Bur, W. A. Cronin, S. Gange, N. Baruch, G. W. Comstock, and R. E. Chaisson. 2006. Delayed tuberculosis diagnosis and tuberculosis transmission. Int J Tuberc Lung Dis 10:24-30.
27.    Dowdy, D. W., R. E. Chaisson, L. H. Moulton, and S. E. Dorman. 2006. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. Aids 20:751-62.
28.    Burman, W. J., S. Goldberg, J. L. Johnson, G. Muzanye, M. Engle, A. W. Mosher, S. Choudhri, C. L. Daley, S. S. Munsiff, Z. Zhao, A. Vernon, and R. E. Chaisson. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174:331-8.
29.    Wilson, D., J. B. Nachega, R. E. Chaisson, and G. Maartens. 2005. Diagnostic yield of peripheral lymph node needle-core biopsies in HIV-infected adults with suspected smear-negative tuberculosis. Int J Tuberc Lung Dis 9:220-2.
30.    Teixeira, E. G., D. Menzies, G. W. Comstock, A. J. Cunha, A. L. Kritski, L. C. Soares, E. Bethlem, G. Zanetti, A. Ruffino-Netto, M. T. Belo, L. Selig, M. M. Branco, D. Cherri, S. Maia, R. Marandino, R. R. Luiz, R. E. Chaisson, and A. Trajman. 2005. Latent tuberculosis infection among undergraduate medical students in Rio de Janeiro State, Brazil. Int J Tuberc Lung Dis 9:841-7.
31.    Nachega, J. B., D. A. Lehman, D. Hlatshwayo, R. Mothopeng, R. E. Chaisson, and A. S. Karstaedt. 2005. HIV/AIDS and Antiretroviral Treatment Knowledge, Attitudes, Beliefs, and Practices in HIV-Infected Adults in Soweto, South Africa. J Acquir Immune Defic Syndr 38:196-201.
32.    Mehta, S. H., D. L. Thomas, M. Torbenson, S. Brinkley, L. Mirel, R. E. Chaisson, R. D. Moore, and M. S. Sulkowski. 2005. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 41:123-31.
33.    Grant, A. D., S. Charalambous, K. L. Fielding, J. H. Day, E. L. Corbett, R. E. Chaisson, K. M. De Cock, R. J. Hayes, and G. J. Churchyard. 2005. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. Jama 293:2719-25.
34.    Golub, J. E., C. I. Mohan, G. W. Comstock, and R. E. Chaisson. 2005. Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis 9:1183-203.
35.    Golub, J. E., S. Bur, W. A. Cronin, S. Gange, T. R. Sterling, B. Oden, N. Baruch, G. W. Comstock, and R. E. Chaisson. 2005. Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. Int J Tuberc Lung Dis 9:392-7.
36.    Golub, J. E., S. Bur, W. A. Cronin, S. Gange, N. Baruch, G. W. Comstock, and R. E. Chaisson. 2005. Patient and health care system delays in pulmonary tuberculosis diagnosis in a low-incidence state. Int J Tuberc Lung Dis 9:992-8.
37.    Sulkowski, M. S., S. H. Mehta, R. E. Chaisson, D. L. Thomas, and R. D. Moore. 2004. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. Aids 18:2277-84.
38.    Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R. J. O'Brien, A. A. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170:1131-4.
39.    Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, R. J. O'Brien, A. N. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169:421-6.
40.    Nachega, J. B., D. M. Stein, D. A. Lehman, D. Hlatshwayo, R. Mothopeng, R. E. Chaisson, and A. S. Karstaedt. 2004. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses 20:1053-6.
41.    Moore, R. D., J. C. Keruly, and R. E. Chaisson. 2004. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 35:46-51.
42.    Mehta, S. H., D. L. Thomas, M. Torbenson, S. Brinkley, L. Mirel, R. E. Chaisson, R. D. Moore, and M. S. Sulkowski. 2004. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 41:123-131.
43.    Karakousis, P. C., R. D. Moore, and R. E. Chaisson. 2004. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis 4:557-65.
44.    Gordin, F. M., D. L. Cohn, J. P. Matts, R. E. Chaisson, and R. J. O'Brien. 2004. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin Infect Dis 39:561-5.
45.    Day, J. H., A. D. Grant, K. L. Fielding, L. Morris, V. Moloi, S. Charalambous, A. J. Puren, R. E. Chaisson, K. M. De Cock, R. J. Hayes, and G. J. Churchyard. 2004. Does tuberculosis increase HIV load? J Infect Dis 190:1677-84.
46.    Charalambous, S., A. D. Grant, J. H. Day, E. Rothwell, R. E. Chaisson, R. J. Hayes, and G. J. Churchyard. 2004. Feasibility and acceptability of a specialist clinical service for HIV-infected mineworkers in South Africa. AIDS Care 16:47-56.
47.    Boyd, S. J., N. F. Thomas-Gosain, A. Umbricht, M. J. Tucker, J. M. Leslie, R. E. Chaisson, and K. L. Preston. 2004. Gender differences in indices of opioid dependency and medical comorbidity in a population of hospitalized HIV-infected African-Americans. Am J Addict 13:281-91.
48.    Sterling, T. R., R. E. Chaisson, J. Keruly, and R. D. Moore. 2003. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis 188:1659-65.
49.    Churchyard, G. J., K. Fielding, S. Charalambous, J. H. Day, E. L. Corbett, R. J. Hayes, R. E. Chaisson, K. M. De Cock, B. Samb, and A. D. Grant. 2003. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? Aids 17:2063-70.
50.    Chaisson, R. E. 2003. Treatment of chronic infections with rifamycins: is resistance likely to follow? Antimicrob Agents Chemother 47:3037-9.
51.    Benson, C. A., P. L. Williams, J. S. Currier, F. Holland, L. F. Mahon, R. R. MacGregor, C. B. Inderlied, C. Flexner, J. Neidig, R. Chaisson, G. F. Notario, and R. Hafner. 2003. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 37:1234-43.
52.    Yoshimatsu, T., E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset. 2002. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother 46:1875-9.
53.    Sulkowski, M. S., D. L. Thomas, S. H. Mehta, R. E. Chaisson, and R. D. Moore. 2002. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35:182-9.
54.    Sulkowski, M. S., D. L. Thomas, S. H. Mehta, R. E. Chaisson, and R. D. Moore. 2002. Reply. Hepatology 36:513-4.
55.    Sulkowski, M. S., R. D. Moore, S. H. Mehta, R. E. Chaisson, and D. L. Thomas. 2002. Hepatitis C and progression of HIV disease. Jama 288:199-206.
56.    Riley, E. D., D. Vlahov, S. Huettner, P. Beilenson, M. Bonds, and R. E. Chaisson. 2002. Characteristics of injection drug users who utilize tuberculosis services at sites of the Baltimore city needle exchange program. J Urban Health 79:113-27.
57.    Oursler, K. K., R. D. Moore, W. R. Bishai, S. M. Harrington, D. S. Pope, and R. E. Chaisson. 2002. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis 34:752-9.
58.    Lucas, G. M., K. A. Gebo, R. E. Chaisson, and R. D. Moore. 2002. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. Aids 16:767-74.
59.    Gounder, C., F. C. De Queiroz Mello, M. B. Conde, W. R. Bishai, A. L. Kritski, R. E. Chaisson, and S. E. Dorman. 2002. Field evaluation of a rapid immunochromatographic test for tuberculosis. J Clin Microbiol 40:1989-93.
60.    Gillini, L. A., A. Cingolani, R. Murri, A. De Luca, S. Di Giambenedetto, A. Wu, R. Cauda, and R. E. Chaisson. 2002. Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 29:546-7.
61.    Chaisson, R. E., J. Armstrong, J. Stafford, J. Golub, and S. Bur. 2002. Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners. Jama 288:165-6.
62.    Bellete, B., J. Coberly, G. L. Barnes, C. Ko, R. E. Chaisson, G. W. Comstock, and W. R. Bishai. 2002. Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis 34:1449-56.
63.    Wendel, K. A., K. S. Alwood, R. Gachuhi, R. E. Chaisson, W. R. Bishai, and T. R. Sterling. 2001. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 120:193-7.
64.    Sterling, T. R., S. E. Dorman, R. E. Chaisson, L. Ding, J. Hackman, K. Moore, and S. M. Holland. 2001. Human immunodeficiency virus-seronegative adults with extrapulmonary tuberculosis have abnormal innate immune responses. Clin Infect Dis 33:976-82.
65.    Sterling, T. R., R. E. Chaisson, and R. D. Moore. 2001. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. Aids 15:2251-7.
66.    Riley, E. D., R. E. Chaisson, T. J. Robnett, J. Vertefeuille, S. A. Strathdee, and D. Vlahov. 2001. Use of audio computer-assisted self-interviews to assess tuberculosis-related risk behaviors. Am J Respir Crit Care Med 164:82-5.
67.    Poundstone, K. E., R. E. Chaisson, and R. D. Moore. 2001. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. Aids 15:1115-23.
68.    Obasanjo, O. O., P. Wu, M. Conlon, L. V. Karanfil, P. Pryor, G. Moler, G. Anhalt, R. E. Chaisson, and T. M. Perl. 2001. An outbreak of scabies in a teaching hospital: lessons learned. Infect Control Hosp Epidemiol 22:13-8.
69.    Moore, R. D., J. C. Keruly, and R. E. Chaisson. 2001. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. Aids 15:617-20.
70.    Lucas, G. M., L. W. Cheever, R. E. Chaisson, and R. D. Moore. 2001. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 27:251-9.
71.    Lucas, G. M., R. E. Chaisson, and R. D. Moore. 2001. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. Aids 15:1679-86.
72.    Keruly, J. C., R. E. Chaisson, and R. D. Moore. 2001. Increasing incidence of avascular necrosis of the hip in hiv-infected patients. J Acquir Immune Defic Syndr 28:101-2.
73.    Golub, J. E., W. A. Cronin, O. O. Obasanjo, W. Coggin, K. Moore, D. S. Pope, D. Thompson, T. R. Sterling, S. Harrington, W. R. Bishai, and R. E. Chaisson. 2001. Transmission of Mycobacterium tuberculosis through casual contact with an infectious case. Arch Intern Med 161:2254-8.
74.    Chaisson, R. E., G. L. Barnes, J. Hackman, L. Watkinson, L. Kimbrough, S. Metha, S. Cavalcante, and R. D. Moore. 2001. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med 110:610-5.
75.    Chaisson, R. E. 2001. AIDS turns 20: reflections on a brief but extraordinary history. Hopkins HIV Rep 13:1, 5.
76.    Sullivan, J. H., R. D. Moore, J. C. Keruly, and R. E. Chaisson. 2000. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med 162:64-7.
77.    Sulkowski, M. S., D. L. Thomas, R. E. Chaisson, and R. D. Moore. 2000. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. Jama 283:74-80.
78.    Sulkowski, M. S., D. L. Thomas, R. E. Chaisson, and R. D. Moore. 2000. Elevated liver enzymes following initiation of antiretroviral therapy. Jama 283:2526-7.
79.    Stringer, J. S., M. Youle, C. Sabin, R. E. Chaisson, and T. R. Sterling. 2000. Selected topics from the 13th International AIDS Conference, July 9-14, 2000. Duran, South Africa. HIV Clin Trials 1:100-11.
80.    Sterling, T. R., D. Thompson, R. L. Stanley, P. D. McElroy, A. Madison, K. Moore, R. Ridzon, S. Harrington, W. R. Bishai, R. E. Chaisson, and S. Bur. 2000. A multi-state outbreak of tuberculosis among members of a highly mobile social network: implications for tuberculosis elimination. Int J Tuberc Lung Dis 4:1066-73.
81.    Sterling, T. R., D. S. Pope, W. R. Bishai, S. Harrington, R. R. Gershon, and R. E. Chaisson. 2000. Transmission of Mycobacterium tuberculosis from a cadaver to an embalmer. N Engl J Med 342:246-8.
82.    Rao, S. N., A. L. Mookerjee, O. O. Obasanjo, and R. E. Chaisson. 2000. Errors in the treatment of tuberculosis in Baltimore. Chest 117:734-7.
83.    Gordin, F., R. E. Chaisson, J. P. Matts, C. Miller, M. de Lourdes Garcia, R. Hafner, J. L. Valdespino, J. Coberly, M. Schechter, A. J. Klukowicz, M. A. Barry, and R. J. O'Brien. 2000. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. Jama 283:1445-50.
84.    Chaisson, R. E., J. C. Keruly, and R. D. Moore. 2000. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. Jama 284:3128-9.
85.    Chaisson, R. E. 2000. New developments in the treatment of latent tuberculosis. Int J Tuberc Lung Dis 4:S176-81.
86.    Chaisson, R. E. 2000. Guidelines for the management of community-acquired pneumonia. Am J Manag Care 6:S1211-5.
87.    Bishai, W., A. B. Brueggemann, D. P. Nicolau, I. Steinberg, E. Spiritus, C. Tanigawa, S. Koenig, R. E. Chaisson, B. A. Browne, and D. M. Yoder. 2000. Roundtable discussion. Optimizing the use of antimicrobial therapy. Am J Manag Care 6:S1222-35.
88.    Sterling, T. R., W. T. Brehm, R. D. Moore, and R. E. Chaisson. 1999. Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world. Int J Tuberc Lung Dis 3:248-54.
89.    Sterling, T. R., K. Alwood, R. Gachuhi, W. Coggin, D. Blazes, W. R. Bishai, and R. E. Chaisson. 1999. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. Aids 13:1899-904.
90.    Oursler, K. A., R. D. Moore, and R. E. Chaisson. 1999. Risk factors for cryptococcal meningitis in HIV-infected patients. AIDS Res Hum Retroviruses 15:625-31.
91.    Moore, R. D., L. Cheever, J. C. Keruly, and R. E. Chaisson. 1999. Lack of sex difference in CD4 to HIV-1 RNA viral load ratio. Lancet 353:463-4.
92.    Moore, R. D., and R. E. Chaisson. 1999. Natural history of HIV infection in the era of combination antiretroviral therapy. Aids 13:1933-42.
93.    Miyazaki, E., M. Miyazaki, J. M. Chen, R. E. Chaisson, and W. R. Bishai. 1999. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 43:85-9.
94.    Miyazaki, E., R. E. Chaisson, and W. R. Bishai. 1999. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. Antimicrob Agents Chemother 43:2126-30.
95.    Lucas, G. M., R. E. Chaisson, and R. D. Moore. 1999. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131:81-7.
96.    Kimura, M., P. J. Converse, J. Astemborski, J. S. Rothel, D. Vlahov, G. W. Comstock, N. M. Graham, R. E. Chaisson, and W. R. Bishai. 1999. Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure. J Infect Dis 179:1297-300.
97.    Gebo, K. A., R. E. Chaisson, J. G. Folkemer, J. G. Bartlett, and R. D. Moore. 1999. Costs of HIV medical care in the era of highly active antiretroviral therapy. Aids 13:963-9.
98.    Gallant, J. E., R. E. Chaisson, J. C. Keruly, and R. D. Moore. 1999. Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients. Aids 13:225-9.
99.    Finzi, D., J. Blankson, J. D. Siliciano, J. B. Margolick, K. Chadwick, T. Pierson, K. Smith, J. Lisziewicz, F. Lori, C. Flexner, T. C. Quinn, R. E. Chaisson, E. Rosenberg, B. Walker, S. Gange, J. Gallant, and R. F. Siliciano. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-7.
100.    De Cock, K. M., and R. E. Chaisson. 1999. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 3:457-65.
101.    Corbett, E. L., L. Blumberg, G. J. Churchyard, N. Moloi, K. Mallory, T. Clayton, B. G. Williams, R. E. Chaisson, R. J. Hayes, and K. M. De Cock. 1999. Nontuberculous mycobacteria: defining disease in a prospective cohort of South African miners. Am J Respir Crit Care Med 160:15-21.
102.    Chaisson, R. E., J. S. Coberly, and K. M. De Cock. 1999. DOTS and drug resistance: a silver lining to a darkening cloud. Int J Tuberc Lung Dis 3:1-3.
103.    Chaisson, R. E. 1999. HIV becomes world's leading infectious cause of death. Hopkins HIV Rep 11:1.
104.    Chaisson, R. E. 1999. Update on treatment and prevention guidelines for HIV-related tuberculosis. Hopkins HIV Rep 11:3,10,12.
105.    Bishai, W. R., and R. E. Chaisson. 1999. Opportunistic infections: down but not out. Hopkins HIV Rep 11:2, 7, 12.
106.    Sulkowski, M. S., R. E. Chaisson, C. L. Karp, R. D. Moore, J. B. Margolick, and T. C. Quinn. 1998. The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis 178:1642-8.
107.    Sterling, T. R., R. D. Moore, N. M. Graham, J. Astemborski, D. Vlahov, and R. E. Chaisson. 1998. Mycobacterium tuberculosis infection and disease are not associated with protection against subsequent disseminated M. avium complex disease. Aids 12:1451-7.
108.    Morris, L., D. J. Martin, T. C. Quinn, and R. E. Chaisson. 1998. The importance of doing HIV research in developing countries. Nat Med 4:1228-9.
109.    Moore, R. D., J. C. Keruly, and R. E. Chaisson. 1998. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 19:29-33.
110.    Manabe, Y. C., D. P. Clark, R. D. Moore, J. A. Lumadue, H. R. Dahlman, P. C. Belitsos, R. E. Chaisson, and C. L. Sears. 1998. Cryptosporidiosis in patients with AIDS: correlates of disease and survival. Clin Infect Dis 27:536-42.
111.    Halsey, N. A., J. S. Coberly, J. Desormeaux, P. Losikoff, J. Atkinson, L. H. Moulton, M. Contave, M. Johnson, H. Davis, L. Geiter, E. Johnson, R. Huebner, R. Boulos, and R. E. Chaisson. 1998. Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 351:786-92.
112.    Halsey, N. A., J. Coberly, and R. Chaisson. 1998. Prevention of tuberculosis in HIV-1. Lancet 352:742.
113.    Gallant, J. E., R. E. Chaisson, and R. D. Moore. 1998. The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications. Chest 114:1258-63.
114.    Eldred, L. J., A. W. Wu, R. E. Chaisson, and R. D. Moore. 1998. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 18:117-25.
115.    Chaisson, R. E., J. E. Gallant, J. C. Keruly, and R. D. Moore. 1998. Impact of opportunistic disease on survival in patients with HIV infection. Aids 12:29-33.
116.    Chaisson, R. E., and W. Bishai. 1998. No news is good news: opportunistic infections. Hopkins HIV Rep 10:2, 11.
117.    Chaisson, R. E. 1998. Short course preventive therapy for tuberculosis is successful in HIV-infected patients. Hopkins HIV Rep 10:2-3.
118.    Bishai, W. R., N. M. Graham, S. Harrington, D. S. Pope, N. Hooper, J. Astemborski, L. Sheely, D. Vlahov, G. E. Glass, and R. E. Chaisson. 1998. Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. Jama 280:1679-84.
119.    Styrt, B. A., R. E. Chaisson, and R. D. Moore. 1997. Prior antimicrobials and staphylococcal bacteremia in HIV-infected patients. Aids 11:1243-8.
120.    Moore, R. D., and R. E. Chaisson. 1997. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. J Acquir Immune Defic Syndr Hum Retrovirol 14:223-31.
121.    Moore, R. D., and R. E. Chaisson. 1997. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 16:15-21.
122.    Michele, T. M., W. A. Cronin, N. M. Graham, D. M. Dwyer, D. S. Pope, S. Harrington, R. E. Chaisson, and W. R. Bishai. 1997. Transmission of Mycobacterium tuberculosis by a fiberoptic bronchoscope. Identification by DNA fingerprinting. Jama 278:1093-5.
123.    Gielen, A. C., R. R. Faden, N. E. Kass, P. O'Campo, R. Chaisson, and L. Watkinson. 1997. Evaluation of an HIV/AIDS education program in an urban prenatal clinic. Womens Health Issues 7:269-78.
124.    Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-300.
125.    Erbelding, E. J., R. E. Chaisson, J. E. Gallant, and R. D. Moore. 1997. Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease. Antivir Ther 2:71-7.
126.    Chaisson, R. E., and R. D. Moore. 1997. Prevention of opportunistic infections in the era of improved antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 16 Suppl 1:S14-22.
127.    Chaisson, R. E., P. Keiser, M. Pierce, W. J. Fessel, J. Ruskin, C. Lahart, C. A. Benson, K. Meek, N. Siepman, and J. C. Craft. 1997. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. Aids 11:311-7.
128.    Bishai, W. R., and R. E. Chaisson. 1997. Short-course chemoprophylaxis for tuberculosis. Clin Chest Med 18:115-22.
129.    Moore, R. D., J. C. Keruly, and R. E. Chaisson. 1996. Duration of the survival benefit of zidovudine therapy in HIV infection. Arch Intern Med 156:1073-7.
130.    Moore, R. D., I. Fortgang, J. Keruly, and R. E. Chaisson. 1996. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 101:34-40.
131.    Moore, R. D., C. P. Chaulk, R. Griffiths, S. Cavalcante, and R. E. Chaisson. 1996. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 154:1013-9.
132.    Moore, R. D., and R. E. Chaisson. 1996. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 124:633-42.
133.    Maenza, J. R., J. C. Keruly, R. D. Moore, R. E. Chaisson, W. G. Merz, and J. E. Gallant. 1996. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 173:219-25.
134.    Janis, E. M., D. W. Allen, M. J. Glesby, L. A. Carey, L. M. Mundy, R. Gopalan, and R. E. Chaisson. 1996. Tuberculin skin test reactivity, anergy, and HIV infection in hospitalized patients. Longcope Firm of the Osler Medical Housestaff. Am J Med 100:186-92.
135.    Gebo, K. A., R. D. Moore, J. C. Keruly, and R. E. Chaisson. 1996. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 173:857-62.
136.    Desormeaux, J., M. P. Johnson, J. S. Coberly, P. Losikoff, E. Johnson, R. Huebner, L. Geiter, H. Davis, J. Atkinson, R. E. Chaisson, R. Boulos, and N. A. Halsey. 1996. Widespread HIV counseling and testing linked to a community-based tuberculosis control program in a high-risk population. Bull Pan Am Health Organ 30:1-8.
137.    Cheever, L. W., R. E. Chaisson, and J. E. Gallant. 1996. Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus. West J Med 165:67-73.
138.    Chaisson, R. E., J. C. Keruly, S. McAvinue, J. E. Gallant, and R. D. Moore. 1996. Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 11:455-9.
139.    Chaisson, R. E., H. C. Clermont, E. A. Holt, M. Cantave, M. P. Johnson, J. Atkinson, H. Davis, R. Boulos, T. C. Quinn, and N. A. Halsey. 1996. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 154:1034-8.
140.    Chaisson, R. E. 1996. Potential role of rifabutin in prophylaxis for tuberculosis and infections due to multiple opportunistic pathogens. Clin Infect Dis 22 Suppl 1:S61-6; discussion S66-9.
141.    Bishai, W. R., N. M. Graham, S. Harrington, C. Page, K. Moore-Rice, N. Hooper, and R. E. Chaisson. 1996. Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N Engl J Med 334:1573-6.
142.    Moore, R. D., J. C. Keruly, and R. E. Chaisson. 1995. Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med 155:1965-70.
143.    Moore, R. D., and R. E. Chaisson. 1995. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. Aids 9:1337-42.
144.    Glesby, M. J., R. D. Moore, and R. E. Chaisson. 1995. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 21:370-5.
145.    Gallant, J. E., R. D. Moore, J. Keruly, D. D. Richman, and R. E. Chaisson. 1995. Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. J Infect Dis 172:346-52.
146.    Gallant, J. E., S. M. McAvinue, R. D. Moore, J. G. Bartlett, D. L. Stanton, and R. E. Chaisson. 1995. The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia. Chest 107:1018-23.
147.    Fortgang, I. S., P. C. Belitsos, R. E. Chaisson, and R. D. Moore. 1995. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 90:1433-6.
148.    Chaulk, C. P., K. Moore-Rice, R. Rizzo, and R. E. Chaisson. 1995. Eleven years of community-based directly observed therapy for tuberculosis. Jama 274:945-51.
149.    Chaisson, R. E., J. C. Keruly, and R. D. Moore. 1995. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 333:751-6.
150.    Chaisson, R. E. 1995. Mycobacterial infections and HIV. Kekkaku 70:313-20.
151.    Chaisson, R. E. 1995. Mycobacterium avium complex and HIV. J Int Assoc Physicians AIDS Care 1:10-5.
152.    Barditch-Crovo, P., and R. E. Chaisson. 1995. Adverse reactions to therapy for HIV infection. Emerg Med Clin North Am 13:133-46.
153.    Stanton, D. L., A. W. Wu, R. D. Moore, S. C. Rucker, M. P. Piazza, J. E. Abrams, and R. E. Chaisson. 1994. Functional status of persons with HIV infection in an ambulatory setting. J Acquir Immune Defic Syndr 7:1050-6.
154.    Small, P. M., P. C. Hopewell, G. F. Schecter, R. E. Chaisson, and P. C. Goodman. 1994. Evolution of chest radiographs in treated patients with pulmonary tuberculosis and HIV infection. J Thorac Imaging 9:74-7.
155.    Moore, R. D., D. Stanton, R. Gopalan, and R. E. Chaisson. 1994. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 330:763-8.
156.    Moore, R. D., J. Hidalgo, J. C. Bareta, and R. E. Chaisson. 1994. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immune Defic Syndr 7:349-54.
157.    Moore, R. D., R. E. Chaisson, and J. Hidalgo. 1994. The efficacy of zidovudine is time limited. Jama 272:1001; discussion 1001-2.
158.    Gallant, J. E., R. D. Moore, D. D. Richman, J. Keruly, and R. E. Chaisson. 1994. Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. Arch Intern Med 154:566-72.
159.    Gallant, J. E., R. D. Moore, and R. E. Chaisson. 1994. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 120:932-44.
160.    Faden, R. R., A. C. Gielen, N. Kass, P. O'Campo, J. Anderson, R. Chaisson, and A. Sheon. 1994. Prenatal HIV-antibody testing and the meaning of consent. AIDS Public Policy J 9:151-9.
161.    Chaulk, C. P., R. E. Chaisson, J. N. Lewis, and R. T. Rizzo. 1994. Treating multidrug-resistant tuberculosis: compliance and side effects. Jama 271:103-4; discussion 105.
162.    Chaisson, R. E., C. A. Benson, M. P. Dube, L. B. Heifets, J. A. Korvick, S. Elkin, T. Smith, J. C. Craft, and F. R. Sattler. 1994. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 121:905-11.
163.    Chaisson, R. E. 1994. Smoking cessation in patients with HIV. Jama 272:564.
164.    Alwood, K., J. Keruly, K. Moore-Rice, D. L. Stanton, C. P. Chaulk, and R. E. Chaisson. 1994. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. Aids 8:1103-8.
165.    Nightingale, S. D., D. W. Cameron, F. M. Gordin, P. M. Sullam, D. L. Cohn, R. E. Chaisson, L. J. Eron, P. D. Sparti, B. Bihari, D. L. Kaufman, and et al. 1993. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 329:828-33.
166.    McDiarmid, M. A., J. Fujikawa, J. Schaefer, G. Weinmann, R. E. Chaisson, and C. A. Hudson. 1993. Health effects and exposure assessment of aerosolized pentamidine handlers. Chest 104:382-5.
167.    Johnson, M. P., and R. E. Chaisson. 1993. Tuberculosis and HIV disease. AIDS Clin Rev:73-93.
168.    Herskowitz, A., D. Vlahov, S. Willoughby, R. E. Chaisson, S. P. Schulman, D. A. Neumann, and K. L. Baughman. 1993. Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. Am J Cardiol 71:955-8.
169.    Graham, N. M., and R. E. Chaisson. 1993. Tuberculosis and HIV infection: epidemiology, pathogenesis, and clinical aspects. Ann Allergy 71:421-8; quiz 428-33.
170.    Glesby, M. J., R. D. Moore, and R. E. Chaisson. 1993. Herpes zoster in patients with advanced human immunodeficiency virus infection treated with zidovudine. Zidovudine Epidemiology Study Group. J Infect Dis 168:1264-8.
171.    Gallant, J. E., L. J. Eldred, J. M. Leslie, R. E. Chaisson, and T. C. Quinn. 1993. Impact of the 1993 revision of the CDC case definition on the performance of the WHO and PAHO clinical case definitions for AIDS. Aids 7:1396-7.
172.    Cotton, D. J., W. G. Powderly, J. Feinberg, D. I. Abrams, R. E. Chaisson, L. J. Wheat, D. M. Finkelstein, V. Tallman, B. Zimmer, R. Berzon, and et al. 1993. Guidelines for the design and conduct of AIDS clinical trials. AIDS Clinical Trials Group. Clin Infect Dis 16:816-22; discussion 823-4.
173.    Chaisson, R. E., D. L. Stanton, J. E. Gallant, S. Rucker, J. G. Bartlett, and R. D. Moore. 1993. Impact of the 1993 revision of the AIDS case definition on the prevalence of AIDS in a clinical setting. Aids 7:857-62.
174.    Samuels, J. F., D. Vlahov, J. C. Anthony, and R. E. Chaisson. 1992. Measurement of HIV risk behaviors among intravenous drug users. Br J Addict 87:417-28.
175.    O'Campo, P., M. A. de Boer, R. R. Faden, A. C. Gielen, N. Kass, and R. Chaisson. 1992. Discrepancies between women's personal interview data and medical record documentation of illicit drug use, sexually transmitted diseases, and HIV infection. Med Care 30:965-71.
176.    Nordback, I. H., J. L. Olson, R. E. Chaisson, and J. L. Cameron. 1992. Acute effects of a nucleoside analog dideoxyinosine (DDI) on the pancreas. J Surg Res 53:610-4.
177.    Moore, R. D., J. Keruly, D. D. Richman, T. Creagh-Kirk, and R. E. Chaisson. 1992. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group. Aids 6:671-7.
178.    McDiarmid, M. A., J. Schaefer, C. L. Richard, R. E. Chaisson, and B. S. Tepper. 1992. Efficacy of engineering controls in reducing occupational exposure to aerosolized pentamidine. Chest 102:1764-6.
179.    Johnson, M. P., J. S. Coberly, H. C. Clermont, R. E. Chaisson, H. L. Davis, P. Losikoff, A. J. Ruff, R. Boulos, and N. A. Halsey. 1992. Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. J Infect Dis 166:194-8.
180.    Gallant, J. E., J. Somani, R. E. Chaisson, D. Stanton, M. Smith, and T. C. Quinn. 1992. Diagnostic accuracy of three clinical case definitions for advanced HIV disease. Aids 6:295-9.
181.    Gallant, J. E., P. S. Mueller, J. C. McArthur, and R. E. Chaisson. 1992. Intramedullary tuberculoma in a patient with HIV infection. Aids 6:889-91.
182.    Gallant, J. E., R. D. Moore, D. D. Richman, J. Keruly, and R. E. Chaisson. 1992. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 166:1223-7.
183.    Galai, N., N. Graham, R. Chaisson, K. E. Nelson, D. Vlahov, and J. Lewis. 1992. Multidrug-resistant tuberculosis. N Engl J Med 327:1172-3; discussion 1174.
184.    Chaisson, R. E., E. Taylor, J. B. Margolick, A. Munoz, L. Solomon, S. Cohn, K. E. Nelson, and D. Vlahov. 1992. Immune serum markers and CD4 cell counts in HIV-infected intravenous drug users. J Acquir Immune Defic Syndr 5:456-60.
185.    Chaisson, R. E., R. D. Moore, D. D. Richman, J. Keruly, and T. Creagh. 1992. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am Rev Respir Dis 146:285-9.
186.    Chaisson, R. E., J. Keruly, D. D. Richman, and R. D. Moore. 1992. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group. Arch Intern Med 152:2009-13.
187.    Chaisson, R. 1992. Clarithromycin is effective against M. avium complex in AIDS. Am Fam Physician 46:1784.
188.    Steinhoff, M. C., B. S. Auerbach, K. E. Nelson, D. Vlahov, R. L. Becker, N. M. Graham, D. H. Schwartz, A. H. Lucas, and R. E. Chaisson. 1991. Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med 325:1837-42.
189.    Small, P. M., G. F. Schecter, P. C. Goodman, M. A. Sande, R. E. Chaisson, and P. C. Hopewell. 1991. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 324:289-94.
190.    Small, P. M., G. F. Schecter, P. C. Goodman, M. A. Sande, R. E. Chaisson, and P. C. Hopewell. 1991. [HIV infection and tuberculosis]. Dtsch Med Wochenschr 116:919.
191.    Moore, R. D., H. Kessler, D. D. Richman, C. Flexner, and R. E. Chaisson. 1991. Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine. Jama 265:2208-11.
192.    Moore, R. D., J. Hidalgo, B. W. Sugland, and R. E. Chaisson. 1991. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 324:1412-6.
193.    Moore, R. D., T. Creagh-Kirk, J. Keruly, G. Link, M. C. Wang, D. Richman, and R. E. Chaisson. 1991. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Zidovudine Epidemiology Study Group. Arch Intern Med 151:981-6.
194.    Levine, B., and R. E. Chaisson. 1991. Mycobacterium kansasii: a cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection. Ann Intern Med 114:861-8.
195.    Lee, B. L., A. M. Padula, R. C. Kimbrough, S. R. Jones, R. E. Chaisson, J. Mills, and M. A. Sande. 1991. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 325:520-1.
196.    Johnson, M. P., and R. E. Chaisson. 1991. Tuberculosis and HIV disease. AIDS Clin Rev:109-26.
197.    Jacobson, M. A., P. Bacchetti, A. Kolokathis, R. E. Chaisson, S. Szabo, B. Polsky, G. T. Valainis, D. Mildvan, D. Abrams, J. Wilber, and et al. 1991. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. Bmj 302:73-8.
198.    Hendrix, C. W., P. A. Volberding, and R. E. Chaisson. 1991. HIV antigen variability in ARC/AIDS. J Acquir Immune Defic Syndr 4:847-50.
199.    Flexner, C., P. A. Barditch-Crovo, D. M. Kornhauser, H. Farzadegan, L. J. Nerhood, R. E. Chaisson, K. M. Bell, K. J. Lorentsen, C. W. Hendrix, B. G. Petty, and et al. 1991. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother 35:2544-50.
200.    Feigal, E., E. Murphy, K. Vranizan, P. Bacchetti, R. Chaisson, J. E. Drummond, W. Blattner, M. McGrath, J. Greenspan, and A. Moss. 1991. Human T cell lymphotropic virus types I and II in intravenous drug users in San Francisco: risk factors associated with seropositivity. J Infect Dis 164:36-42.
201.    Easterbrook, P. J., J. C. Keruly, T. Creagh-Kirk, D. D. Richman, R. E. Chaisson, and R. D. Moore. 1991. Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group. Jama 266:2713-8.
202.    Chaisson, R. E., and S. McAvinue. 1991. Control of tuberculosis during aerosol therapy administration. Respir Care 36:1017-25.
203.    Chaisson, R. E., E. Fuchs, D. L. Stanton, T. C. Quinn, C. Hendricksen, J. G. Bartlett, and H. Farzadegan. 1991. Racial heterogeneity of HIV antigenemia in people with HIV infection. Aids 5:177-80.
204.    Barbacci, M., J. T. Repke, and R. E. Chaisson. 1991. Routine prenatal screening for HIV infection. Lancet 337:709-11.
205.    Barbacci, M., J. T. Repke, and R. E. Chaisson. 1991. HIV testing urged for pregnancy. Nurs Times 87:11.
206.    Theuer, C. P., P. C. Hopewell, D. Elias, G. F. Schecter, G. W. Rutherford, and R. E. Chaisson. 1990. Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis 162:8-12.
207.    Ng, V. L., N. A. Virani, R. E. Chaisson, D. M. Yajko, H. T. Sphar, K. Cabrian, N. Rollins, P. Charache, M. Krieger, W. K. Hadley, and et al. 1990. Rapid detection of Pneumocystis carinii using a direct fluorescent monoclonal antibody stain. J Clin Microbiol 28:2228-33.
208.    Lemp, G. F., S. F. Payne, G. W. Rutherford, N. A. Hessol, W. Winkelstein, Jr., J. A. Wiley, A. R. Moss, R. E. Chaisson, R. T. Chen, D. W. Feigal, Jr., and et al. 1990. Projections of AIDS morbidity and mortality in San Francisco. Jama 263:1497-501.
209.    Chaisson, R. E., and M. D. Smith. 1990. Pneumocystis carinii pneumonia: diagnosis and management. Md Med J 39:365-9.
210.    Chaisson, R. E., and D. E. Griffin. 1990. Progressive multifocal leukoencephalopathy in AIDS. Jama 264:79-82.
211.    Chaisson, R. E. 1990. Living with AIDS. Jama 263:434-6.
212.    Chaisson, R. E. 1990. Prevention of opportunistic infections in patients with HIV. Md Med J 39:156-60.
213.    Barbacci, M. B., G. A. Dalabetta, J. T. Repke, B. L. Talbot, P. Charache, B. F. Polk, and R. E. Chaisson. 1990. Human immunodeficiency virus infection in women attending an inner-city prenatal clinic: ineffectiveness of targeted screening. Sex Transm Dis 17:122-6.
214.    Jacobson, M. A., D. I. Abrams, P. A. Volberding, P. Bacchetti, J. Wilber, R. E. Chaisson, S. Crowe, W. Howard, and A. Moss. 1989. Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. J Infect Dis 159:1029-36.
215.    Chaisson, R. E., and G. Slutkin. 1989. Tuberculosis and human immunodeficiency virus infection. J Infect Dis 159:96-100.
216.    Chaisson, R. E., and P. C. Hopewell. 1989. Mycobacteria and AIDS mortality. Am Rev Respir Dis 139:1-3.
217.    Chaisson, R. E., P. Bacchetti, D. Osmond, B. Brodie, M. A. Sande, and A. R. Moss. 1989. Cocaine use and HIV infection in intravenous drug users in San Francisco. Jama 261:561-5.
218.    Chaisson, R. E. 1989. Bacterial pneumonia in patients with human immunodeficiency virus infection. Semin Respir Infect 4:133-8.
219.    Chaisson, R. E. 1989. Tuberculosis and HIV infection--new opportunities for an old pathogen. West J Med 150:687-9.
220.    Rosenthal, P. J., R. E. Chaisson, W. K. Hadley, and J. H. Leech. 1988. Rectal leishmaniasis in a patient with acquired immunodeficiency syndrome. Am J Med 84:307-9.
221.    Osmond, D., P. Bacchetti, R. E. Chaisson, T. Kelly, R. Stempel, J. Carlson, and A. R. Moss. 1988. Time of exposure and risk of HIV infection in homosexual partners of men with AIDS. Am J Public Health 78:944-8.
222.    Moss, A. R., P. Bacchetti, D. Osmond, W. Krampf, R. E. Chaisson, D. Stites, J. Wilber, J. P. Allain, and J. Carlson. 1988. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) 296:745-50.
223.    Chaisson, R. E., M. D. Leuther, J. P. Allain, S. Nusinoff-Lehrman, G. S. Boone, D. Feigal, and P. Volberding. 1988. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial. Arch Intern Med 148:2151-3.
224.    Chaisson, R. E. 1988. Infections due to encapsulated bacteria, Salmonella, Shigella, and Campylobacter. Infect Dis Clin North Am 2:475-84.
225.    Bacchetti, P., D. Osmond, R. E. Chaisson, S. Dritz, G. W. Rutherford, L. Swig, and A. R. Moss. 1988. Survival patterns of the first 500 patients with AIDS in San Francisco. J Infect Dis 157:1044-7.
226.    Osmond, D., R. Chaisson, A. Moss, P. Bacchetti, and W. Krampf. 1987. Lymphadenopathy in asymptomatic patients seropositive for HIV. N Engl J Med 317:246.
227.    Leoung, G. S., R. E. Chaisson, and J. Mills. 1987. Comparison of nosocomial infections due to Staphylococcus aureus and enterococci in a general hospital. Surg Gynecol Obstet 165:339-42.
228.    Chaisson, R. E., G. F. Schecter, C. P. Theuer, G. W. Rutherford, D. F. Echenberg, and P. C. Hopewell. 1987. Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis 136:570-4.
229.    Chaisson, R. E., D. Osmond, A. R. Moss, H. W. Feldman, and P. Bernacki. 1987. HIV, bleach, and needle sharing. Lancet 1:1430.
230.    Chaisson, R. E., A. R. Moss, R. Onishi, D. Osmond, and J. R. Carlson. 1987. Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. Am J Public Health 77:169-72.
231.    Chaisson, R. E., and P. C. Hopewell. 1987. Empiric diagnosis of Pneumocystis pneumonia. Jama 258:3385.
232.    Celum, C. L., R. E. Chaisson, G. W. Rutherford, J. L. Barnhart, and D. F. Echenberg. 1987. Incidence of salmonellosis in patients with AIDS. J Infect Dis 156:998-1002.
233.    Chaisson, R. E., J. Ross, J. L. Gerberding, and M. A. Sande. 1986. Clinical aspects of adult epiglottitis. West J Med 144:700-3.
234.    Chaisson, R. E., J. P. Allain, M. Leuther, and P. A. Volberding. 1986. Significant changes in HIV antigen level in the serum of patients treated with azidothymidine. N Engl J Med 315:1610-1.

 

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

U.S. 1-410-464-6713 (toll free)
International +1-410-614-6424

 

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer